World's Best Scientists 2026 revealed!
Victoria M. Richon

Victoria M. Richon

D-Index & Metrics

Biology and Biochemistry

D-Index
84
Citations
41361
World Ranking
3236
National Ranking
1638

Overview

Victoria M. Richon is affiliated with Entact Bio in the United States and has contributed significantly to cancer research, focusing particularly on PARP inhibition in cancer therapy. Their research spans multiple aspects of oncology, molecular biology, epidemiology, physiology, and immunology, with a concentration on signaling pathways and immune responses relevant to cancer treatment.

Their recent publications reflect a focus on the role of PARP enzymes and their inhibition in cancer models and immune signaling. These papers include:

  • PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, 2021, Cancer Cell
  • A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants, 2021, Cell Chemical Biology
  • Abstract DDT02-01: RBN-2397: A first-in-class PARP7 inhibitor targeting a newly discovered cancer vulnerability in stress-signaling pathways, 2020, Cancer Research
  • Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models, 2022, Cancer Research
  • The PARP14 inhibitor RBN-3143 suppresses lung inflammation in preclinical models, 2022, 05.01 - Airway pharmacology and treatment

The primary themes in their work concentrate on:

  • PARP inhibition in cancer therapy
  • Interferon and immune responses
  • Cancer immunotherapy and biomarkers
  • Signaling pathways in disease
  • Autophagy in disease and therapy
  • Antimicrobial resistance in Staphylococcus
  • Calcium signaling and nucleotide metabolism

Victoria M. Richon has collaborated extensively with several scientists, with frequent co-authors including Melissa M. Vasbinder, Mario Niepel, Kevin W. Kuntz, Ryan Abo, and Kristy Kuplast-Barr.

The bulk of their publications have appeared mainly in the venues of Cancer Research, Cancer Cell, and Cell Chemical Biology, with seven publications in Cancer Research and individual contributions to other specialized journals.

Their expertise lies predominantly within the field of Medicine, with 13 documented publications. Subfields show a strong emphasis on Oncology, reflected in 10 publications, followed by studies in Molecular Biology, Epidemiology, Physiology, and Immunology.

Best Publications

  • Histone deacetylases and cancer: causes and therapies.

    Paul A. Marks;Richard A. Rifkind;Victoria M. Richon;Ronald Breslow

  • Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

    Michael S. Finnin;Jill R. Donigian;Alona Cohen;Victoria M. Richon

  • Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells

    Paul A. Marks;Victoria M. Richon;Richard A. Rifkind

  • Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

    Victoria M. Richon;Todd W. Sandhoff;Richard A. Rifkind;Paul A. Marks

  • Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

    William Kevin Kelly;Owen A. O'Connor;Lee M. Krug;Judy H. Chiao

  • A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases

    Victoria M. Richon;Stephane Emiliani;Eric Verdin;Yael Webb

  • Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

    E. Hockly;V.M. Richon;B. Woodman;D.L. Smith

  • Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor

    Scott R. Daigle;Edward J. Olhava;Carly A. Therkelsen;Christina R. Majer

  • MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L

    Kathrin M. Bernt;Nan Zhu;Amit U. Sinha;Sridhar Vempati

  • A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

    Sarah K Knutson;Tim J Wigle;Natalie M Warholic;Christopher J Sneeringer

  • Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2

    Sarah K. Knutson;Natalie M. Warholic;Tim J. Wigle;Christine R. Klaus

  • Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

    Lisa M. Butler;David B. Agus;Howard I. Scher;Brian Higgins

  • Histone deacetylase inhibitors as new cancer drugs.

    Paul A. Marks;Victoria M. Richon;Ronald Breslow;Richard A. Rifkind

  • Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas

    Christopher J. Sneeringer;Margaret Porter Scott;Kevin W. Kuntz;Sarah K. Knutson

  • Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

    Scott R. Daigle;Edward J. Olhava;Carly A. Therkelsen;Aravind Basavapathruni

  • Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone Deacetylase

    Raymond P. Warrell;Li-Zhen He;Victoria Richon;Elizabeth Calleja

  • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications

    Constantine S. Mitsiades;Nicholas S. Mitsiades;Ciaran J. McMullan;Vassiliki Poulaki

  • The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin

    Lisa M. Butler;Xianbo Zhou;Wei-Sheng Xu;Howard I. Scher

  • Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

    Melissa J. Peart;Gordon K. Smyth;Ryan K. van Laar;David D. Bowtell

  • Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

    V M Richon;Y Webb;R Merger;T Sheppard

Frequent Co-Authors

Robert A. Copeland
Robert A. Copeland Accent Therapeutics (United States)
Paul A. Marks
Paul A. Marks Columbia University
Richard A. Rifkind
Richard A. Rifkind Memorial Sloan Kettering Cancer Center
Ronald Breslow
Ronald Breslow Columbia University
Lisa M. Butler
Lisa M. Butler University of Adelaide
Scott A. Armstrong
Scott A. Armstrong Harvard University
George Sgouros
George Sgouros Johns Hopkins University
Kapil N. Bhalla
Kapil N. Bhalla The University of Texas MD Anderson Cancer Center
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Timothy J. Mitchison
Timothy J. Mitchison Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Victoria M. Richon

Trending Scientists

Recently Published Articles